← All trials
NCT01321255
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2012
- Primary completion
- May 1, 2014
- Completion date
- Jun 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 2118
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Universidad Carlos III MadridLead sponsor
- Universidad Carlos III MadridOverall official - principal investigator
- Universidad Carlos III MadridCollaborator
- Universidad Carlos III MadridStudy director
- World Health OrganizationCollaborator
- Ferrer Internacional S.A.Collaborator
- University of BarcelonaCollaborator
- Rusculleda Foundation Instituto DAMICCollaborator
- ARTTIC International Management ServicesCollaborator
- Mario Negri InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.